S10 Ep44: Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer

OncLive® On Air - Un pódcast de OncLive® On Air

prueba podimo gratis durante 60 días!

Miles de audiolibros y podcasts exclusivos, haz clic aquí para probar

Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.